Chronic obstructive pulmonary disease(COPD) is an incompletely reversible and progressive pulmonary disease characterized by airflow restriction, which is the third leading cause of death worldwide, accounting for 6% of all deaths worldwide. Acute exacerbation (AE) of COPD can accelerate the decline of lung function, worsening pulmonary symptoms, and increase the risk of death in patients. Health education, inhaled technical guidance training, individual self-management, psychological counseling, home oxygen therapy, nutritional support, and other comprehensive interventions can help improve the lung function of COPD patients, alleviate clinical symptoms, improve the quality of life. While a number of COPD applications have been developed, few provide comprehensive assessment and guidance for these kinds of patients. Therefore, the investigators aim to establish a bundle care mode based on the mode of "hospital-home-community-patient", clarify the impact of the management on prognosis, and evaluate the effect of mobile medical-assisted bundle management mode. In this randomized controlled trial(RCT), AECOPD patients will be divided into interventional or control groups randomly. Patients in the interventional group will receive mobile medication and standard of care at the same time (bundle care mode). While patients in the control group will receive standard of care only (traditional management mode). This study will be conducted to compare the effects of traditional and bundle care modes, and to formulate the implementation path and specifications of bundle care for AECOPD patients after discharge in China.

Inclusion Criteria:

• AECOPD Patients with pulmonary function grade GOLD2-4;
• Aged between 45 and 70 years old;
• Have a smartphone, and can skillfully use mobile Wechat official account;
• Willing to use Wechat official accounts to manage COPD;
• Willing to accept outpatient follow-up;
• Signed informed consent.

Exclusion Criteria:

• Patients with asthma, bronchiectasis, tuberculosis, or other diseases;
• Patients with malignant tumors, liver and kidney failure, limb dyskinesia, and other diseases;
• Unstable angina pectoris in recent one month, myocardial infarction within a half year, severe arrhythmia, uncontrollable congestive heart failure, or poor blood pressure control (systolic blood pressure > 140mmHg and/or diastolic blood pressure > 90mmHg);
• Cognitive impairment;
• Combined with respiratory failure;
• With a life expectancy of less than one year;
• Plan to or participating in a COPD management project or mobile Wechat official account project;
• Completed another trial within 30 days.